search
Back to results

A Clinical Study in Healthy Women Which Aims to Explore the Intestinal Uptake of Two Different Tablets of GRTA9906 Into the Body and the Effect of Food on it

Primary Purpose

Pain, Neuropathic Pain, Chronic Pain

Status
Completed
Phase
Phase 1
Locations
Germany
Study Type
Interventional
Intervention
GRTA9906 60 mg PR tablet
GRTA9906 60 mg IR capsule
Sponsored by
Grünenthal GmbH
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pain

Eligibility Criteria

18 Years - 55 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Female Caucasian volunteers aged 18 - 55 years.
  • Body mass index between 18 and 29 kilograms per square meter inclusive.
  • Good physical and mental health status (no current acute illness) determined on the basis of the medical history and a general clinical examination.
  • Normal supine blood pressure (systolic blood pressure greater than or equal to 90 Millimeter mercury (mmHg) and less than or equal to 145 mmHg, diastolic blood pressure greater than or equal to 45mmHg and less than or equal to 90 mmHg) and pulse (greater than or equal to 45 and less than or equal to 90 beats per minute).
  • Electrocardiogram (12 lead) considered as normal by the Investigator.
  • Results of laboratory tests within the normal ranges for the testing laboratory. The Investigator may include a participant having values outside the accepted range if, in his/her opinion, these values are of no clinical relevance. The decision will be justified.
  • Participants giving written consent to participate in this trial.
  • Negative pregnancy test (females of childbearing potential only).
  • Adequate contraception (females of childbearing potential only; adequate contraception is defined as any form of hormonal contraception or intra-uterine device that needs to be in place for a period of at least 2 months prior to screening. Additional barrier contraception must be used for the duration of the study, defined as from the time of screening to the post-study medical examination, and for at least one full month thereafter. A single barrier method alone or abstinence alone is not acceptable. Women of non-childbearing potential may be included if surgically sterile or post-menopausal for at least 2 years).
  • Must be able to tolerate high-fat and high-calorie study-meal.

Exclusion Criteria:

  • Diseases and functional disorders of the gastrointestinal tract, hepatobiliary system, renal system or cardiovascular system including marked repolarisation abnormality (e.g. suspicious or definite congenital long QT syndrome) or co-medication that is known to influence cardiac repolarisation substantially.
  • Malignancy.
  • History of orthostatic hypotension.
  • Positive human immunodeficiency virus HIV1/2-antibodies, hepatitis B surface-antigen (HBs), hepatitis B core-antibodies (HBc), Hepatitis C virus (HCV) antibody tests at the prestudy medical examination.
  • Drug allergy.
  • Bronchial asthma.
  • Participation in another clinical study in the last three months before starting this study (exception: characterisation of metaboliser status).
  • Blood donation (more than 100 milliliter) in the last three months before the start of the study.
  • Evidence of alcohol, medication or drug abuse.
  • Positive drug abuse screening test.
  • Extremely unbalanced diet (in the opinion of the investigator).
  • Excessive consumption of food or beverages containing caffeine or other xanthines (more than five cups of coffee or equivalent per day).
  • Smoking of more than 20 cigarettes per day.
  • Known or suspected of not being able to comply with the study protocol.
  • Neurotic personality, psychiatric illness, or suicide risk.
  • History of seizures or at risk (i.e. head trauma, epilepsy in family anamnesis, unclear loss of consciousness).
  • Pregnant or breastfeeding.

Sites / Locations

  • Dept. of Human Pharmacology

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

GRTA9906 60 mg PR tablet (fed)

GRTA9906 60 mg PR tablet (fasting)

GRTA9906 60 mg IR capsule (fed)

GRTA9906 60 mg IR capsule (fasting)

Arm Description

Participants will receive two 60 mg GRTA9906 PR matrix tablets under fed conditions after consumption of a high-fat and high-calorie test meal.

Participants will receive two 60 mg GRTA9906 PR matrix tablets under fasting conditions (10 hours before dosing until 4.5 hours after dosing).

Participants will receive two 60 mg GRTA9906 IR capsules under fed conditions after consumption of a high-fat and high-calorie test meal.

Participants will receive two 60 mg GRTA9906 IR capsules under fasting conditions (10 hours before dosing until 4.5 hours after dosing).

Outcomes

Primary Outcome Measures

Pharmacokinetic parameter - AUC0-tz
Area under the concentration vs. time curve from dosing time to the last measured concentration above the lower limit of quantitation. The concentration of GRTA9906 was determined in the serum samples using a validated HPLC-method with fluorometric detection.
Pharmacokinetic parameter - AUC0-inf
Total area under the concentration vs. time curve (from dosing time to infinity). The concentration of GRTA9906 was determined in the serum samples using a validated HPLC-method with fluorometric detection.
Pharmacokinetic parameter - tmax
Time to reach maximum serum concentration. The concentration of GRTA9906 was determined in the serum samples using a validated HPLC-method with fluorometric detection.
Pharmacokinetic parameter - Cmax
Maximum serum concentration. The concentration of GRTA9906 was determined in the serum samples using a validated HPLC-method with fluorometric detection.
Pharmacokinetic parameter - lag-time (tlag)
Period of time from the administration of the investigational product to the first measured concentration. The concentration of GRTA9906 was determined in the serum samples using a validated HPLC-method with fluorometric detection.
Pharmacokinetic parameter - t(½,z)
Apparent terminal half-life. The concentration of GRTA9906 was determined in the serum samples using a validated HPLC-method with fluorometric detection.
Pharmacokinetic parameter - MRT
Mean residence time. The concentration of GRTA9906 was determined in the serum samples using a validated HPLC-method with fluorometric detection.
Pharmacokinetic parameter - HVD
Half-value duration. The concentration of GRTA9906 was determined in the serum samples using a validated HPLC-method with fluorometric detection.
Pharmacokinetic parameter - CL/f
Total clearance. The concentration of GRTA9906 was determined in the serum samples using a validated HPLC-method with fluorometric detection.
Pharmacokinetic parameter - Vz/f
Apparent volume of distribution during the terminal phase. The concentration of GRTA9906 was determined in the serum samples using a validated HPLC-method with fluorometric detection.

Secondary Outcome Measures

Pupillometry parameter - Initial diameter (mm)
Diameter in millimeter (mm) before presentation of the light stimulus. Pupillometry will be carried out using a Compact Integrated Pupillograph (CIP) in a darkened room.
Pupillometry parameter - Latency time (sec)
Time in seconds (sec) between begin of the light stimulus and onset of pupil reaction.
Pupillometry parameter - Amplitude (mm)
Difference in millimeter (mm) between initial value and minimum diameter.
Pupillometry parameter - Constriction time (sec)
Time in seconds (sec) between onset of reaction and minimum diameter.

Full Information

First Posted
December 4, 2018
Last Updated
December 4, 2018
Sponsor
Grünenthal GmbH
search

1. Study Identification

Unique Protocol Identification Number
NCT03765801
Brief Title
A Clinical Study in Healthy Women Which Aims to Explore the Intestinal Uptake of Two Different Tablets of GRTA9906 Into the Body and the Effect of Food on it
Official Title
Phase I, Single-center Study to Explore the Relative Bioavailability and the Effect of Food on the Bioavailability of Prolonged Release Tablets Compared to Immediate Release Capsules Each Containing 60 mg of GRTA9906 in 20 Healthy Female Volunteers
Study Type
Interventional

2. Study Status

Record Verification Date
December 2018
Overall Recruitment Status
Completed
Study Start Date
October 22, 2003 (Actual)
Primary Completion Date
December 11, 2003 (Actual)
Study Completion Date
December 11, 2003 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Grünenthal GmbH

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The aim of this clinical study in healthy women is to explore the intestinal uptake (bioavailability) of two different tablets of GRTA9906 (formulations) into the body and the effect of food on it. The intake of food may considerably influence the bioavailability, either by interaction with the compound itself or, if a prolonged release (PR) formulation is used, with the components of the tablet-matrix. For these reasons, the relative bioavailability and the effect of food on the bioavailability of GRTA9906 given as PR tablets compared to immediate release (IR) capsules will be assessed in this study. During the 4 periods of the study, each participant will receive two 60 mg GRTA9906 PR matrix tablets and two 60 mg GRTA9906 IR capsules under fed conditions (after consumption of a high-fat and high-calorie test meal) and fasting conditions (10 hours before dosing until 4.5 hours after dosing). In each period, the participant will receive the investigational product once.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Neuropathic Pain, Chronic Pain, Visceral Pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
22 (Actual)

8. Arms, Groups, and Interventions

Arm Title
GRTA9906 60 mg PR tablet (fed)
Arm Type
Experimental
Arm Description
Participants will receive two 60 mg GRTA9906 PR matrix tablets under fed conditions after consumption of a high-fat and high-calorie test meal.
Arm Title
GRTA9906 60 mg PR tablet (fasting)
Arm Type
Experimental
Arm Description
Participants will receive two 60 mg GRTA9906 PR matrix tablets under fasting conditions (10 hours before dosing until 4.5 hours after dosing).
Arm Title
GRTA9906 60 mg IR capsule (fed)
Arm Type
Experimental
Arm Description
Participants will receive two 60 mg GRTA9906 IR capsules under fed conditions after consumption of a high-fat and high-calorie test meal.
Arm Title
GRTA9906 60 mg IR capsule (fasting)
Arm Type
Experimental
Arm Description
Participants will receive two 60 mg GRTA9906 IR capsules under fasting conditions (10 hours before dosing until 4.5 hours after dosing).
Intervention Type
Drug
Intervention Name(s)
GRTA9906 60 mg PR tablet
Intervention Description
GRTA9906 60 mg PR tablet
Intervention Type
Drug
Intervention Name(s)
GRTA9906 60 mg IR capsule
Intervention Description
GRTA9906 60 mg IR capsule
Primary Outcome Measure Information:
Title
Pharmacokinetic parameter - AUC0-tz
Description
Area under the concentration vs. time curve from dosing time to the last measured concentration above the lower limit of quantitation. The concentration of GRTA9906 was determined in the serum samples using a validated HPLC-method with fluorometric detection.
Time Frame
pre-dose, 5, 10, 20, 30, 45 minutes, and 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 13, 16, 20, and 23 hours post-dose
Title
Pharmacokinetic parameter - AUC0-inf
Description
Total area under the concentration vs. time curve (from dosing time to infinity). The concentration of GRTA9906 was determined in the serum samples using a validated HPLC-method with fluorometric detection.
Time Frame
pre-dose, 5, 10, 20, 30, 45 minutes, and 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 13, 16, 20, and 23 hours post-dose
Title
Pharmacokinetic parameter - tmax
Description
Time to reach maximum serum concentration. The concentration of GRTA9906 was determined in the serum samples using a validated HPLC-method with fluorometric detection.
Time Frame
pre-dose, 5, 10, 20, 30, 45 minutes, and 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 13, 16, 20, and 23 hours post-dose
Title
Pharmacokinetic parameter - Cmax
Description
Maximum serum concentration. The concentration of GRTA9906 was determined in the serum samples using a validated HPLC-method with fluorometric detection.
Time Frame
pre-dose, 5, 10, 20, 30, 45 minutes, and 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 13, 16, 20, and 23 hours post-dose
Title
Pharmacokinetic parameter - lag-time (tlag)
Description
Period of time from the administration of the investigational product to the first measured concentration. The concentration of GRTA9906 was determined in the serum samples using a validated HPLC-method with fluorometric detection.
Time Frame
pre-dose, 5, 10, 20, 30, 45 minutes, and 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 13, 16, 20, and 23 hours post-dose
Title
Pharmacokinetic parameter - t(½,z)
Description
Apparent terminal half-life. The concentration of GRTA9906 was determined in the serum samples using a validated HPLC-method with fluorometric detection.
Time Frame
pre-dose, 5, 10, 20, 30, 45 minutes, and 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 13, 16, 20, and 23 hours post-dose
Title
Pharmacokinetic parameter - MRT
Description
Mean residence time. The concentration of GRTA9906 was determined in the serum samples using a validated HPLC-method with fluorometric detection.
Time Frame
pre-dose, 5, 10, 20, 30, 45 minutes, and 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 13, 16, 20, and 23 hours post-dose
Title
Pharmacokinetic parameter - HVD
Description
Half-value duration. The concentration of GRTA9906 was determined in the serum samples using a validated HPLC-method with fluorometric detection.
Time Frame
pre-dose, 5, 10, 20, 30, 45 minutes, and 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 13, 16, 20, and 23 hours post-dose
Title
Pharmacokinetic parameter - CL/f
Description
Total clearance. The concentration of GRTA9906 was determined in the serum samples using a validated HPLC-method with fluorometric detection.
Time Frame
pre-dose, 5, 10, 20, 30, 45 minutes, and 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 13, 16, 20, and 23 hours post-dose
Title
Pharmacokinetic parameter - Vz/f
Description
Apparent volume of distribution during the terminal phase. The concentration of GRTA9906 was determined in the serum samples using a validated HPLC-method with fluorometric detection.
Time Frame
pre-dose, 5, 10, 20, 30, 45 minutes, and 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 13, 16, 20, and 23 hours post-dose
Secondary Outcome Measure Information:
Title
Pupillometry parameter - Initial diameter (mm)
Description
Diameter in millimeter (mm) before presentation of the light stimulus. Pupillometry will be carried out using a Compact Integrated Pupillograph (CIP) in a darkened room.
Time Frame
pre-dose and 1, 2, 3, 4, 5, 6, 7, 8, 10 and 23 hours post-dose
Title
Pupillometry parameter - Latency time (sec)
Description
Time in seconds (sec) between begin of the light stimulus and onset of pupil reaction.
Time Frame
pre-dose and 1, 2, 3, 4, 5, 6, 7, 8, 10 and 23 hours post-dose
Title
Pupillometry parameter - Amplitude (mm)
Description
Difference in millimeter (mm) between initial value and minimum diameter.
Time Frame
pre-dose and 1, 2, 3, 4, 5, 6, 7, 8, 10 and 23 hours post-dose
Title
Pupillometry parameter - Constriction time (sec)
Description
Time in seconds (sec) between onset of reaction and minimum diameter.
Time Frame
pre-dose and 1, 2, 3, 4, 5, 6, 7, 8, 10 and 23 hours post-dose

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Female Caucasian volunteers aged 18 - 55 years. Body mass index between 18 and 29 kilograms per square meter inclusive. Good physical and mental health status (no current acute illness) determined on the basis of the medical history and a general clinical examination. Normal supine blood pressure (systolic blood pressure greater than or equal to 90 Millimeter mercury (mmHg) and less than or equal to 145 mmHg, diastolic blood pressure greater than or equal to 45mmHg and less than or equal to 90 mmHg) and pulse (greater than or equal to 45 and less than or equal to 90 beats per minute). Electrocardiogram (12 lead) considered as normal by the Investigator. Results of laboratory tests within the normal ranges for the testing laboratory. The Investigator may include a participant having values outside the accepted range if, in his/her opinion, these values are of no clinical relevance. The decision will be justified. Participants giving written consent to participate in this trial. Negative pregnancy test (females of childbearing potential only). Adequate contraception (females of childbearing potential only; adequate contraception is defined as any form of hormonal contraception or intra-uterine device that needs to be in place for a period of at least 2 months prior to screening. Additional barrier contraception must be used for the duration of the study, defined as from the time of screening to the post-study medical examination, and for at least one full month thereafter. A single barrier method alone or abstinence alone is not acceptable. Women of non-childbearing potential may be included if surgically sterile or post-menopausal for at least 2 years). Must be able to tolerate high-fat and high-calorie study-meal. Exclusion Criteria: Diseases and functional disorders of the gastrointestinal tract, hepatobiliary system, renal system or cardiovascular system including marked repolarisation abnormality (e.g. suspicious or definite congenital long QT syndrome) or co-medication that is known to influence cardiac repolarisation substantially. Malignancy. History of orthostatic hypotension. Positive human immunodeficiency virus HIV1/2-antibodies, hepatitis B surface-antigen (HBs), hepatitis B core-antibodies (HBc), Hepatitis C virus (HCV) antibody tests at the prestudy medical examination. Drug allergy. Bronchial asthma. Participation in another clinical study in the last three months before starting this study (exception: characterisation of metaboliser status). Blood donation (more than 100 milliliter) in the last three months before the start of the study. Evidence of alcohol, medication or drug abuse. Positive drug abuse screening test. Extremely unbalanced diet (in the opinion of the investigator). Excessive consumption of food or beverages containing caffeine or other xanthines (more than five cups of coffee or equivalent per day). Smoking of more than 20 cigarettes per day. Known or suspected of not being able to comply with the study protocol. Neurotic personality, psychiatric illness, or suicide risk. History of seizures or at risk (i.e. head trauma, epilepsy in family anamnesis, unclear loss of consciousness). Pregnant or breastfeeding.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Grünenthal Study Director
Organizational Affiliation
Grünenthal GmbH
Official's Role
Study Director
Facility Information:
Facility Name
Dept. of Human Pharmacology
City
Aachen
ZIP/Postal Code
52078
Country
Germany

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Clinical Study in Healthy Women Which Aims to Explore the Intestinal Uptake of Two Different Tablets of GRTA9906 Into the Body and the Effect of Food on it

We'll reach out to this number within 24 hrs